August Bulletin
Issue 59
Community Notices | News | Jobs | Funding | Events
Community Notices
No August seminar
There will be no seminar this month; next seminar is Monday September 20th, 4-5pm (currently planned as hybrid format at the Koch Institute’s Luria auditorium).
Symposium on “Engineering the Next Wave of Immunotherapy”
The 19th Annual Koch Institute Summer Symposium will be held virtually on September 17, 2021, and will focus on cancer immunotherapy.
In the News
A non-invasive test to detect cancer cells and pinpoint their location
(MIT News) In a new study, Dr. Sangeeta Bhatia and her colleagues showed that the diagnostic could be used to monitor the progression of colon cancer, including the spread of metastatic tumors to the lung and the liver. Eventually, they hope it could be developed into a routine cancer test that could be performed annually. Read more…
Enhancing drug delivery with ultrasound
(MIT News) Suono Bio’s technology is the culmination of more than three decades of discoveries made in MIT labs by researchers including Dr. Carl Schoellhammer and fellow Suono co-founders Drs. Robert Langer, who is the David H. Koch Institute Professor at MIT, and Giovanni Traverso, an assistant professor at MIT. The platform takes advantage of a phenomena in which ultrasound waves create little jets in liquid that can be used to push drugs into cells. Read more…
Six technologies that could revolutionise the world
(Management Today) Some innovations are on the list of “next big things” for so long that even their most die-hard advocates lose faith in them. mRNA has been trumpeted as a potential medical marvel ever since the first successful clinical trial using the tech was carried out in 1990. Various problems have been painstakingly ironed out over the decades since, and several vaccine trials for rabies, Zika and flu have been chugging along for years. For vaccines, the mRNA platforms’ principal advantage is speed. “You can have an idea in the morning, and a vaccine prototype by evening,” says Daniel Anderson, an mRNA therapy researcher at MIT. Read more…
M13 Therapeutics officially launches 🚀
Dr. Paula Hammond is the inaugural recipient of the @BlackinCancer Distinguished Investigator Award!
Congratulations Paula Hammond, you do such important research and we are absolutely thrilled to have you recognised as the inaugural recipient of this award! 🥳🤩 https://t.co/zQdTiVl6ZL
— BlackinCancer (@BlackinCancer) August 4, 2021
Jobs
Various research positions, Seqirus, Inc.
Seqirus Inc., a vaccine company with its research division located in Cambridge, MA, will have several new positions open for researchers at all levels (bachelors, masters, PhD) interested in working on mRNA vaccines. Candidates with experience related to lipid nanoparticle RNA formulation and lipid design and screening are of particular interest. Please see https://www.seqirus.com/careers to apply or contact eric.dane@seqirus.com (formerly member of the Irvine Lab) for more information.
Non-Viral Vector Biology Lead, Intellia Therapeutics.
Intellia is seeking an innovative scientist with experience delivering RNA and DNA into mammalian cells using non-viral methods. The ideal candidate thrives on working collaboratively with multidisciplinary teams, displays outstanding communication skills, and is passionate about pioneering new gene-editing technologies to treat human diseases. As the Non-Viral Vector Biology Lead, you will build and oversee a team to advance Intellia’s gene-editing platform and pipeline. This role will apply new approaches to engineer and optimize non-viral payloads for gene editing. This role is cross-functional and will work closely with team members in groups across the organization including disease biology, pre-clinical, manufacturing, bioinformatics, and formulations. Read more…
Funding opportunities
| Funding Source | Grant ID | Deadline | Cancer Research Program (PRCRP) Impact award (pre-proposals) | W81XWH-21 | August 18, 2021 |
|---|---|---|
| NIH/NCI: Toward Translation of Nanotechnology Cancer Interventions | PAR-20-116 | November 18, 2021 |
